Myriem Boufraqech

National Cancer Institute — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

25h-index2.2kcitations117works0.52yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer, Hypoxia, and Metabolism(35), Thyroid Cancer Diagnosis and Treatment(24), Microbial metabolism and enzyme function(19), Adrenal and Paraganglionic Tumors(13), Cancer, Lipids, and Metabolism(13)

Publications116 total

Dual targeting of BRAFV600E and ferroptosis results in synergistic anticancer activity via iron overload and enhanced oxidative stress
Journal of Experimental & Clinical Cancer Research·2026· 1 citedOpen Access
Additional file 1 of Dual targeting of BRAFV600E and ferroptosis results in synergistic anticancer activity via iron overload and enhanced oxidative stress
Figshare·2026Open Access
Dual targeting of BRAFV600E and ferroptosis results in synergistic anticancer activity via iron overload and enhanced oxidative stress
Figshare·2026Open Access
Dual targeting of BRAFV600E and ferroptosis results in synergistic anticancer activity via iron overload and enhanced oxidative stress
Figshare·2026Open Access
Additional file 1 of Dual targeting of BRAFV600E and ferroptosis results in synergistic anticancer activity via iron overload and enhanced oxidative stress
Figshare·2026Open Access
Corrigendum to “Combination nitazoxanide and auranofin treatment has synergistic anticancer activity in anaplastic thyroid cancer through enhanced activation of oxidative stress that leads to apoptosis” [Cancer Letters 633 (2025) 217990]
Cancer Letters·2025Open Access
Combination nitazoxanide and auranofin treatment has synergistic anticancer activity in anaplastic thyroid cancer through enhanced activation of oxidative stress that leads to apoptosis
Cancer Letters·2025
CRISPR-Based Gene Dependency Screens reveal Mechanism of BRAF Inhibitor Resistance in Anaplastic Thyroid Cancer
2025· 1 citedOpen Access
Dual Targeting of <i> BRAF <sup>V600E</sup> </i> and Ferroptosis Results in Synergistic Anticancer Activity via Iron Overload and Enhanced Oxidative Stress
2025· 1 citedOpen Access
Abstract 6274: Integrated multi-omics revealed the involvement of MYC and mTOR pathways in radiation resistance of adrenocortical cancer
Cancer Research·2024
Metabolism‐focused CRISPR screen unveils mitochondrial pyruvate carrier 1 as a critical driver for PARP inhibitor resistance in lung cancer
Molecular Carcinogenesis·2024· 2 citedOpen Access
Metabolism-focused CRISPR screen unveils Mitochondrial Pyruvate Carrier 1 as a critical driver for PARP inhibitor resistance in lung cancer
2023Open Access
Data from Identification of Niclosamide as a Novel Anticancer Agent for Adrenocortical Carcinoma
2023Open Access
APPENDIX 3 from Metformin Targets Mitochondrial Glycerophosphate Dehydrogenase to Control Rate of Oxidative Phosphorylation and Growth of Thyroid Cancer &lt;i&gt;In Vitro&lt;/i&gt; and &lt;i&gt;In Vivo&lt;/i&gt;
2023Open Access
Appendix 1 from Metformin Targets Mitochondrial Glycerophosphate Dehydrogenase to Control Rate of Oxidative Phosphorylation and Growth of Thyroid Cancer &lt;i&gt;In Vitro&lt;/i&gt; and &lt;i&gt;In Vivo&lt;/i&gt;
2023Open Access
Data from A Combinatorial Strategy for Targeting &lt;i&gt;BRAF&lt;/i&gt;&lt;sup&gt;V600E&lt;/sup&gt;-Mutant Cancers with BRAF&lt;sup&gt;V600E&lt;/sup&gt; Inhibitor (PLX4720) and Tyrosine Kinase Inhibitor (Ponatinib)
2023Open Access
Data from Dual Inhibition of HDAC and Tyrosine Kinase Signaling Pathways with CUDC-907 Inhibits Thyroid Cancer Growth and Metastases
2023Open Access
Supplementary information from A Combinatorial Strategy for Targeting &lt;i&gt;BRAF&lt;/i&gt;&lt;sup&gt;V600E&lt;/sup&gt;-Mutant Cancers with BRAF&lt;sup&gt;V600E&lt;/sup&gt; Inhibitor (PLX4720) and Tyrosine Kinase Inhibitor (Ponatinib)
2023Open Access
Supplemental Figure 3 from Lysyl Oxidase (LOX) Transcriptionally Regulates &lt;i&gt;SNAI2&lt;/i&gt; Expression and TIMP4 Secretion in Human Cancers
2023Open Access
Supplemental Figure 5 from Lysyl Oxidase (LOX) Transcriptionally Regulates &lt;i&gt;SNAI2&lt;/i&gt; Expression and TIMP4 Secretion in Human Cancers
2023Open Access
page 1 of 6Next →

Frequent Co-authors

Electron Kebebew(35), Naris Nilubol(23), Dhaval Patel(16), Urbain Weyemi(13), Lisa Zhang(12), Lisa Zhang(11), Min Shen(10), Sudheer Kumar Gara(10), Martha Quezado(9), Yaqin Zhang(8), Yue Liu(7), Amit Mehta(6), Haojian Li(6), Meenu Jain(5), Ryan J. Ellis(5), Mei He(5), Samira M. Sadowski(5), Sean Davis(5), Crystal N. Wilson(5), Hui Bai(5)